Immunocore Holdings (IMCR) Invested Capital (2019 - 2026)

Immunocore Holdings has disclosed Invested Capital across 8 years of filings, most recently posting $393.7 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $393.7 million, up 4.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $393.7 million (up 4.01% YoY), and the FY2025 annual result was $381.0 million, up 5.63% from the prior year.
• Invested Capital came in at $393.7 million for Q1 2026 at Immunocore Holdings, up from $381.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $487.5 million in Q4 2022 to a low of $341.3 million in Q1 2023.
• The 5-year median for Invested Capital is $373.3 million (2023), against an average of $378.6 million.
• Across the five-year window, Invested Capital surged 73.22% in 2022 and fell 24.34% in 2023, its largest moves.
• Immunocore Holdings' Invested Capital stood at $487.5 million in 2022, then decreased by 24.34% to $368.8 million in 2023, then slipped by 2.2% to $360.7 million in 2024, then gained by 5.63% to $381.0 million in 2025, then increased by 3.32% to $393.7 million in 2026.
• The last three Invested Capital figures came in at $393.7 million (Q1 2026), $381.0 million (Q4 2025), and $396.6 million (Q3 2025), per Business Quant data.